Brief: BriaCell's Phase 3 Patient Enrollment On Track For 1H2026 Topline Data Readout
09/12/2025 12:31
Dec 9 (Reuters) - Briacell Therapeutics Corp BCT.TO: BRIACELL’S PHASE 3 PATIENT ENROLLMENT ON TRACK FOR 1H2026 TOPLINE DATA READOUT BRIACELL THERAPEUTICS CORP - TOPLINE INTERIM DATA READOUT EXPECTED IN 1H2026 Source text: ID:nGNX6V21Mb Further company coverage: BCT.TO ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Briacell Therapeutics
See all newsBrief: Briacell Therapeutics Prices 1.45 Million Common Shares At $3.25 Per Share
Brief: Briacell Receives Positive Recommendation From Data Safety Monitoring Board (Dsmb) For Phase 3 Study In Metastatic Breast Cancer
Brief: Briacell Expands Pipeline To Include An Ovarian Cancer Immunotherapy Candidate, Bria-Ova+™
Brief: Briacell Phase 3 Bria-Imt™ Study Enrollment Surpasses 230 Patients
Brief: Briacell Adds Nyu Langone Health’S Perlmutter Cancer Center As Clinical Site In Pivotal Phase 3 Breast Cancer Study